DDrare: Database of Drug Development for Rare Diseases

7. 大脳皮質基底核変性症
［臨床試験数：16，薬物数：33（DrugBank：11），標的遺伝子数：6，標的パスウェイ数：13］

Searched query = "Corticobasal degeneration", "Corticobasal syndrome", "CBD"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 18F-AV-1451; 18F-FDG; 18F-RO6958948; ABBV-8E12; AL; Anti-Parkinson medication; BIIB092; BOTULINUM TOXIN TYPE A; Botulinum toxin type A; Davunetide; Davunetide (AL-108, NAP); Device: Deep Brain Stimulation; Diagnostic Test: Elecsys (Roche) Abeta42, Ttau and Ptau; Diagnostic Test: Flutemetamol F18 Injection; Diagnostic Test: Lumipulse (Fujirebio) Abeta42, Ttau and Ptau; Diagnostic Test: [18F]-RO6958948; Dopamine; Flortaucipir; Flortaucipir F18; Flutemetamol; Flutemetamol F18; Leucine; Lithium; NT 101; Other: 13C6 Leucine; Procedure: Brain PET scan; Raclopride; TPI 287 2 mg/m2; TPI-287 20 mg/m2; TPI-287 6.3 mg/m2; Vizamyl; Vizamyl (flutemetamol(F-18)); Xeomin

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02133846 (ClinicalTrials.gov)	May 2014	6/5/2014	Safety Study of TPI-287 to Treat CBS and PSP	A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI 287 in Patients With Primary Four Repeat Tauopathies: Corticobasal Syndrome or Progressive Supranuclear Palsy	Primary Four Repeat Tauopathies (4RT);Corticobasal Syndrome (CBS);Progressive Supranuclear Palsy (PSP);Corticobasal Degeneration (CBD)	Drug: TPI 287 2 mg/m2;Drug: TPI-287 20 mg/m2;Drug: Placebo;Drug: TPI-287 6.3 mg/m2	University of California, San Francisco	CBD Solutions;Tau Consortium	Completed	50 Years	85 Years	All	44	Phase 1	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT02133846
(ClinicalTrials.gov)

May 2014

6/5/2014

Safety Study of TPI-287 to Treat CBS and PSP

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI 287 in Patients With Primary Four Repeat Tauopathies: Corticobasal Syndrome or Progressive Supranuclear Palsy

Primary Four Repeat Tauopathies (4RT);Corticobasal Syndrome (CBS);Progressive Supranuclear Palsy (PSP);Corticobasal Degeneration (CBD)

Drug: TPI 287 2 mg/m2;Drug: TPI-287 20 mg/m2;Drug: Placebo;Drug: TPI-287 6.3 mg/m2

University of California, San Francisco

CBD Solutions;Tau Consortium

Completed

50 Years

85 Years

All

Phase 1

United States